Aclaris Therapeutics (NASDAQ: ACRS) reported Q4 EPS of ($0.37), $0.01 worse than the analyst estimate of ($0.36). Revenue for the quarter came in at $1.5 million versus the consensus estimate of $1.79 million.

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.